BeyondSpring, Inc.
NASDAQ:
BYSI
BeyondSpring, Inc. develops innovative immuno-oncology cancer therapies with a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using an ubiquitination platform. BeyondSpring's lead asset, plinabulin, is in two phase 3 global clinical trials as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and the prevention of chemotherapy-induced neutropenia (CIN).
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Ernst & Young Hua Ming LLP
IPO (March 9, 2017)
Delaware
New York, New York, USA
Ashley R. Robinson, Internal
617-430-7577
Analyst Coverage
Latest News
June 17, 2021: BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update | BeyondSpring (beyondspringpharma.com)
June 16, 2021: BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update | BeyondSpring (beyondspringpharma.com)
May 11, 2021: BeyondSpring to Present at the Bank of America Securities (globenewswire.com)
March 12, 2021: BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
April 30, 2021: BeyondSpring Files 2020 Annual Report on Form 20-F | BeyondSpring (beyondspringpharma.com)